Mechanistic view of risk factors for venous thromboembolism
PH Reitsma, HH Versteeg… - … , thrombosis, and vascular …, 2012 - Am Heart Assoc
Venous thromboembolism is an episodic disease with an annual incidence of 2 to 3/1000
per year that is associated with a high morbidity and mortality. Risk factors for venous …
per year that is associated with a high morbidity and mortality. Risk factors for venous …
Venous and pulmonary thromboembolism and combined hormonal contraceptives. Systematic review and meta-analysis
F Martínez, I Ramírez, E Pérez-Campos… - … European Journal of …, 2012 - Taylor & Francis
Objective A systematic review of studies published between January 1995 and April 2010
aimed at determining the effect of combined hormonal contraceptives (CHCs), administered …
aimed at determining the effect of combined hormonal contraceptives (CHCs), administered …
Hormonal contraception in women at risk of vascular and metabolic disorders: guidelines of the French Society of Endocrinology
P Gourdy, A Bachelot, S Catteau-Jonard… - Annales d' …, 2012 - Elsevier
Hormonal contraceptive methods are widely used in France, including not only oral estrogen–
progestin combinations but also non-oral estrogen–progestin delivery methods (patches …
progestin combinations but also non-oral estrogen–progestin delivery methods (patches …
Progestin-only contraception and venous thromboembolism
MA Blanco-Molina, M Lozano, A Cano, I Cristobal… - Thrombosis research, 2012 - Elsevier
Combined oral contraceptives (COC) are the most popular contraceptive method in
developed countries. Since their introduction there have been numerous changes and …
developed countries. Since their introduction there have been numerous changes and …
Oral contraception in women with mild thrombophilia: What have we learned recently?
Á Blanco-Molina - Thrombosis Research, 2012 - Elsevier
Mild thrombophilias include heterozygous forms of Factor V Leiden and prothrombin
G20210A mutation and high levels of factor VIII. These defects are responsible for only a …
G20210A mutation and high levels of factor VIII. These defects are responsible for only a …
The APC-PCI concentration as an early marker of activation of blood coagulation: a study of women on combined oral contraceptives
K Bremme, RR Hamad, E Berg, K Strandberg… - Thrombosis research, 2012 - Elsevier
BACKGROUND: The risk of venous tromboembolism (VTE) in women taking combined oral
contraceptives (COCs) is attributed to changes in coagulation and fibrinolysis. The impact of …
contraceptives (COCs) is attributed to changes in coagulation and fibrinolysis. The impact of …
Flow-simulated thrombin generation profiles as a predictor of thrombotic risk among pre-menopausal women
SW Jordan, MA Corriere, CY Vossen… - Thrombosis and …, 2012 - thieme-connect.com
A large number of individuals are at risk for deep venous thrombosis (DVT) due to
alterations in multiple coagulation factors and inhibitors secondary to malignancy, drug …
alterations in multiple coagulation factors and inhibitors secondary to malignancy, drug …
Evaluation of the coagulation profile among oral and vaginal combined hormonal contraceptive users using sonoclot coagulation analyzer
Combined hormonal contraceptives possess an inherent risk of thrombus-related events.
The purpose of this study is to elucidate alterations in the coagulation profile among young …
The purpose of this study is to elucidate alterations in the coagulation profile among young …
[PDF][PDF] Hormonal contraception in women at risk for vascular or metabolic diseases: Guidelines of the French society of endocrinology.
P Gourdy, A Bachelot, S Catteau-Jonard… - portailvasculaire.fr
Résumé Le recours aux méthodes contraceptives hormonales est très répandu en France,
incluant principalement les pilules œstroprogestatives, mais également les contraceptions …
incluant principalement les pilules œstroprogestatives, mais également les contraceptions …
エストラジオールによるプロテインS 遺伝子の発現抑制機構
鈴木敦夫 - 日本血栓止血学会誌, 2012 - jstage.jst.go.jp
トロゲンは細胞膜を通過して, 細胞質内に発現している ERα と結合する. 形成されたエストロゲン-
ERα 複合体は核内へと移行し, 転写因子となって標的遺伝子の発現調節を行うが, その機序は …
ERα 複合体は核内へと移行し, 転写因子となって標的遺伝子の発現調節を行うが, その機序は …